You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 217192


✉ Email this page to a colleague

« Back to Dashboard


NDA 217192 describes EPINEPHRINE, which is a drug marketed by Armstrong Pharms, Am Regent, Amneal, Bpi Labs, Fresenius Kabi Usa, Gland, Intl Medication Sys, Hospira, Teva Pharms Usa, and Baxter Hlthcare Corp, and is included in fourteen NDAs. It is available from fifteen suppliers. Additional details are available on the EPINEPHRINE profile page.

The generic ingredient in EPINEPHRINE is epinephrine bitartrate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate profile page.
Summary for 217192
Tradename:EPINEPHRINE
Applicant:Am Regent
Ingredient:epinephrine
Patents:0
Suppliers and Packaging for NDA: 217192
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EPINEPHRINE epinephrine SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 217192 ANDA American Regent, Inc. 0517-3030 0517-3030-01 1 VIAL in 1 CARTON (0517-3030-01) / 1 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSStrengthEQ 30MG BASE/30ML (EQ 1MG BASE/ML)
Approval Date:Sep 6, 2024TE:APRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.